There is a two-step process behind every annual flu and COVID vaccine recommendation in the United States, and most Americans have never had reason to think about it — because it has always quietly worked. This year, the process has broken down in the middle, and understanding exactly where the gap is explains a genuinely confusing situation many readers will encounter this fall.
On May 28, 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to recommend that the fall 2026–2027 COVID-19 vaccine target the XFG strain, and the FDA formally adopted that recommendation the following day. That part of the process — determining which strain the vaccine should target — is complete and settled.
What has not happened is the second step: an official recommendation, from the CDC’s Advisory Committee on Immunization Practices (ACIP), establishing who should receive the vaccine and how its costs are covered by insurance. ACIP has had no functioning quorum since March 2026.
Why This Matters
These are two genuinely distinct regulatory functions, and conflating them is the source of most public confusion about the current situation. The FDA’s role is to evaluate vaccine safety and efficacy and determine the scientifically appropriate formulation. In this case, which COVID variant strain the fall vaccine should target to provide the best match against the circulating virus. That technical work is complete.
ACIP’s role is different: it determines the practical, population-level recommendation — which age groups and risk categories should receive the vaccine, on what schedule, and critically, it is ACIP’s recommendation that legally triggers the requirement for private insurers to cover the vaccine without cost-sharing under the Affordable Care Act, and that determines whether the vaccine is provided free to eligible children through the Vaccines for Children program.
Without ACIP’s second step, a vaccine can be FDA-approved and manufactured, yet have no official, legally binding guidance establishing who should get it or how it will be paid for.
What We Know So Far
The XFG strain recommendation followed the FDA’s standard process for selecting the annual updated COVID vaccine composition, mirroring the well-established system used for decades to select annual flu vaccine strains based on global viral surveillance data. This part of the system functioned normally and on a typical timeline in 2026.
The breakdown is specifically in ACIP. As detailed in MedicalDaily’s prior coverage of the broader ACIP crisis, the committee has been without a functioning quorum since a March 16, 2026 federal court ruling found that most of HHS Secretary Robert F. Kennedy Jr.’s appointed committee members were “distinctly unqualified.” Since then, HHS has rewritten the committee’s charter twice, and an underlying lawsuit from the American Academy of Pediatrics and other medical organizations remains active and unresolved.
CIDRAP’s tracking confirms that, as of late June 2026, no ACIP meeting has been convened with sufficient members to vote on a formal fall 2026 COVID vaccine recommendation, despite the FDA’s strain recommendation having been finalized more than a month earlier.
What Happens in a Normal Year, for Comparison
In a typical year, this process moves smoothly and largely outside public attention. The FDA’s vaccine advisory committee meets in late spring to recommend a strain composition based on global surveillance data — generally mirroring the parallel process used for influenza vaccines for decades. Manufacturers then begin production based on that recommendation over the summer. ACIP meets, typically in the same general timeframe or shortly after, to vote on the population-level recommendation: which ages and risk groups should receive the vaccine, whether it should be a universal recommendation or limited to specific groups, and the schedule.
Once the CDC director formally accepts ACIP’s recommendation — historically close to automatic — it becomes the official U.S. government vaccine recommendation, which then activates insurance coverage requirements under the ACA and Vaccines for Children program eligibility.
In 2026, the first step occurred on schedule. The second step has simply not occurred because the body responsible for it does not currently have the quorum needed to vote.
The Manufacturing-Ahead-of-Policy Problem
Federal procurement records reviewed by CIDRAP show that in early June 2026, the CDC invested approximately $1.24 billion in COVID-19 vaccine contracts with both Pfizer and Sanofi — indicating that vaccine manufacturing and government procurement are proceeding on a normal timeline, even though the formal policy recommendation that would normally accompany that procurement has not been issued.
HHS Secretary Kennedy has disputed characterizing these contracts as completed purchases, describing them instead as indefinite delivery agreements intended to “ensure availability if needed” — language that itself reflects the unusual, provisional position the federal government finds itself in this year, manufacturing and stockpiling a vaccine for a recommendation that has not yet been formally issued.
What Doctors and Experts Say
Public health researchers tracking this situation consistently emphasize that the gap is not a sign that the vaccine is unsafe or that the science has changed — the FDA’s safety and efficacy review process and its strain selection proceeded normally. The gap is specifically administrative and legal: the mechanism that would normally translate FDA’s scientific recommendation into a population-level public health recommendation, with associated insurance coverage requirements, has stalled due to the unrelated legal dispute over ACIP’s membership and charter.
As CIDRAP’s analysis frames it directly: fall respiratory vaccine recommendations “have to come from somewhere,” and the absence of ACIP action does not eliminate that practical necessity — it simply leaves the question of who will fill that role, and when, genuinely open.
What This Means for Your Fall Vaccine Plans
If you are planning to get a COVID booster this fall, the practical reality is this: a vaccine targeting the XFG strain is very likely to be manufactured and available at pharmacies, based on current procurement activity. What remains uncertain is whether, at the time you go to get it, there will be a finalized federal recommendation establishing that your insurance must cover it without cost-sharing, or that it will be provided free if your child is enrolled in the Vaccines for Children program.
Who Is Most Affected?
- Privately insured Americans whose no-cost-sharing vaccine coverage under the ACA depends on a finalized ACIP recommendation
- Medicare and Medicaid beneficiaries whose coverage policy follows ACIP guidance
- Families with children enrolled in the Vaccines for Children program
- Pharmacists and primary care providers, who need official guidance to counsel patients accurately about coverage and eligibility
What You Can Do Now
- Plan to get your fall COVID booster as you normally would — vaccine availability based on the FDA-approved XFG strain formulation is proceeding on a largely normal manufacturing timeline.
- Closer to fall, contact your insurance provider directly to confirm coverage terms for the updated COVID vaccine, given the current uncertainty around ACIP’s formal recommendation.
- If you have a child in the Vaccines for Children program, ask your pediatrician’s office for the most current guidance, as providers are closely monitoring whether and when ACIP issues its recommendation.
- Follow CIDRAP’s ongoing, detailed tracking of the ACIP quorum situation for the most current updates on this evolving process gap.
What Happens Next
The underlying American Academy of Pediatrics v. Kennedy lawsuit remains active, with an expedited appeal request pending. Whether ACIP regains a functioning quorum before fall vaccination season begins in earnest — typically September — remains the single most important open question determining whether this process gap will be resolved in time, or whether the 2026 fall vaccination season will proceed without the normal, legally clear coverage framework Americans have relied on in prior years. MedicalDaily will report on any ACIP meeting, vote, or quorum resolution as it occurs.
The Bottom Line
The FDA has done its job: the fall 2026–27 COVID vaccine will target the XFG strain, a scientific and regulatory decision that is final and settled. What remains genuinely unresolved is the second, equally necessary step — an official ACIP recommendation establishing who should get the vaccine and how it is covered by insurance — because the committee responsible for that decision has had no functioning quorum since March. Vaccine manufacturing is proceeding regardless; the policy framework that normally accompanies it is not. That gap is the source of the confusion many Americans are likely to encounter this fall, and it remains open.
